Senolytic Drug Combo Reverses Age-Related Bone Loss in Mice

Age-related bone loss in the jaw poses significant dental health challenges, but the underlying mechanisms and potential treatments remain poorly understood. This study investigated whether senolytic therapy could address this problem by targeting cellular aging processes.

Researchers compared alveolar bone health between young (2-month) and aged (18-month) mice, then treated aged mice with dasatinib and quercetin (D+Q), a senolytic drug combination known to clear senescent cells. They measured bone resorption markers, periodontal ligament health, and inflammatory indicators.

Aged mice showed clear signs of bone deterioration: increased distance between the tooth's cementoenamel junction and alveolar bone crest, thinner periodontal ligaments, and imbalanced bone metabolism. These changes coincided with accumulation of senescent cells, elevated inflammatory signaling (SASP), and increased neutrophil infiltration.

D+Q treatment significantly improved multiple aspects of bone health in aged mice. The therapy reduced bone resorption markers, enhanced periodontal ligament thickness, and restored more balanced bone metabolism. Importantly, it cleared senescent cells, reduced inflammatory signaling, and decreased neutrophil aggregation in bone tissue.

These findings suggest that cellular senescence contributes to age-related alveolar bone loss and that senolytic therapy could offer a novel treatment approach. However, this mouse study requires validation in human trials before clinical application.